TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSXV:ARCH.VN and OTC-BB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) in a new dosing arm of the trial.
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)
Globe Newswire - Mon Feb 14, 2022 Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)